Advanced in Chorea

Dr. Aaron L. Ellenbogen

Neurology
Corewell Health
Michigan Institute For Neurological Disorders (MIND)
28595 Orchard Lake Road, Suite 200, 
Farmington Hills, MI 
On Staff At
Accepting New Patients
Offers Telehealth
28 Years of Experience

Advanced in Chorea
Corewell Health
Michigan Institute For Neurological Disorders (MIND)
28595 Orchard Lake Road, Suite 200, 
Farmington Hills, MI 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Aaron Ellenbogen is a Neurologist in Farmington Hills, Michigan. Dr. Ellenbogen has been practicing medicine for over 28 years and is rated as an Advanced provider by MediFind in the treatment of Chorea. His top areas of expertise are Movement Disorders, Parkinson's Disease, Drug Induced Dyskinesia, Essential Tremor, and Deep Brain Stimulation. Dr. Ellenbogen is currently accepting new patients.

His clinical research consists of co-authoring 32 peer reviewed articles and participating in 17 clinical trials. MediFind looks at clinical research from the past 15 years.

Graduate Institution
Michigan State University, College Of Osteopathic Medicine, 1998
Residency
Corewell Health Farmington Hills Hospital
Specialties
Neurology
Licenses
Psychiatry & Neurology in MI
Board Certifications
American Osteopathic Board Of Neurology & Psychiatry
Fellowships
Henry Ford Hospital
Hospital Affiliations
Corewell Health Farmington Hills Hospital
Corewell Health William Beaumont University Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Alliance Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
McLaren Health
  • HMO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Meridian Choice
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Priority Health
  • HMO
  • POS
Spectrum Priority Health
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
TeamCare
  • OTHER COMMERCIAL
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
University of Michigan Health
  • HMO
  • INSURANCE PLAN
  • MEDICARE MAPD
Upper Peninsula Health Plan
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 16 Less Insurance Carriers -

Locations

Michigan Institute for Neurological Disorders (MIND)
28595 Orchard Lake Road, Suite 200, Farmington Hills, MI 48334
Call: 248-553-0010
Other Locations
Michigan Institute for Neurological Disorders (MIND)
25100 Kelly Road, Roseville, MI 48066
Call: 248-553-0010

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


16 Clinical Trials

A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease
A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: December 17, 2025
Intervention Type: Drug
Study Drug: Donanemab
Study Phase: Phase 3
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: August 29, 2025
Intervention Type: Drug
Study Drug: Donanemab
Study Phase: Phase 3
Phase 2A, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BTRX-246040 in Parkinson's Disease Subjects With Motor Fluctuations
Phase 2A, Double-blind, Placebo-controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of BTRX-246040 in Parkinson's Disease Subjects With Motor Fluctuations
Enrollment Status: Completed
Publish Date: June 24, 2025
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Randomized, Active-controlled, Double-blind, Double-dummy, Parallel-group Clinical Trial, Investigating the Efficacy, Safety, and Tolerability of Continuous Subcutaneous ND0612 Infusion in Comparison to Oral IR-LD/CD in Subjects With Parkinson's Disease Experiencing Motor Fluctuations (BouNDless)
A Multicenter, Randomized, Active-controlled, Double-blind, Double-dummy, Parallel-group Clinical Trial, Investigating the Efficacy, Safety, and Tolerability of Continuous Subcutaneous ND0612 Infusion in Comparison to Oral IR-LD/CD in Subjects With Parkinson's Disease Experiencing Motor Fluctuations (BouNDless)
Enrollment Status: Active_not_recruiting
Publish Date: May 21, 2025
Intervention Type: Drug, Combination product
Study Drugs: ND0612 Solution, Carbidopa, Levodopa
Study Phase: Phase 3
A Randomized, Placebo-Controlled, Double-Blind Study of ATH-1017 Treatment in Subjects With Parkinson's Disease Dementia or Dementia With Lewy Bodies
A Randomized, Placebo-Controlled, Double-Blind Study of ATH-1017 Treatment in Subjects With Parkinson's Disease Dementia or Dementia With Lewy Bodies
Enrollment Status: Terminated
Publish Date: March 04, 2025
Intervention Type: Drug
Study Drug: ATH-1017
Study Phase: Phase 2
Rostock International Parkinson's Disease Study: an International, Multicenter, Epidemiological Observational Study
Rostock International Parkinson's Disease Study: an International, Multicenter, Epidemiological Observational Study
Enrollment Status: Active_not_recruiting
Publish Date: September 20, 2024
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2 Study of ABP-450 (prabotulinumtoxinA) Purified Neurotoxin Complex for the Prevention of Migraine Headache
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2 Study of ABP-450 (prabotulinumtoxinA) Purified Neurotoxin Complex for the Prevention of Migraine Headache
Enrollment Status: Completed
Publish Date: September 04, 2024
Intervention Type: Drug
Study Drug: ABP-450
Study Phase: Phase 2
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of CVN424 in Parkinson's Disease Patients With Motor Fluctuations
A Phase II, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of CVN424 in Parkinson's Disease Patients With Motor Fluctuations
Enrollment Status: Completed
Publish Date: July 03, 2024
Intervention Type: Drug
Study Drug: CVN424
Study Phase: Phase 2
A Randomized, Double-blind, Placebo-Controlled, 2-Period Crossover, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral TAK-071 in Parkinson Disease Patients With Cognitive Impairment and an Elevated Risk of Falls
A Randomized, Double-blind, Placebo-Controlled, 2-Period Crossover, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral TAK-071 in Parkinson Disease Patients With Cognitive Impairment and an Elevated Risk of Falls
Enrollment Status: Completed
Publish Date: May 14, 2024
Intervention Type: Drug
Study Drug: TAK-071
Study Phase: Phase 2
A Phase 2, Randomized, Double-Blind, Multicenter, Placebo Controlled Study to Evaluate the Safety and Efficacy of Intramuscular ABP-450 (prabotulinumtoxinA) Injection for the Treatment of Cervical Dystonia
A Phase 2, Randomized, Double-Blind, Multicenter, Placebo Controlled Study to Evaluate the Safety and Efficacy of Intramuscular ABP-450 (prabotulinumtoxinA) Injection for the Treatment of Cervical Dystonia
Enrollment Status: Completed
Publish Date: February 14, 2024
Intervention Type: Drug
Study Drug: ABP-450
Study Phase: Phase 2
A Multi-Center, Single-Dose, Multiple-Dose, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered ENT-01 for the Treatment of Parkinson's Disease Related Constipation
A Multi-Center, Single-Dose, Multiple-Dose, Double-Blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Orally Administered ENT-01 for the Treatment of Parkinson's Disease Related Constipation
Enrollment Status: Completed
Publish Date: December 27, 2023
Intervention Type: Other, Drug
Study Phase: Phase 1/Phase 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of Posiphen® in Subjects With Early Alzheimer's Disease (AD) or Early Parkinson's Disease (PD)
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Effects of Posiphen® in Subjects With Early Alzheimer's Disease (AD) or Early Parkinson's Disease (PD)
Enrollment Status: Completed
Publish Date: February 28, 2023
Intervention Type: Drug
Study Drug: Posiphen
Study Phase: Phase 1/Phase 2
A Phase 2 Study to Assess the Effect of TD-9855 in Subjects With Neurogenic Orthostatic Hypotension
A Phase 2 Study to Assess the Effect of TD-9855 in Subjects With Neurogenic Orthostatic Hypotension
Enrollment Status: Completed
Publish Date: September 26, 2022
Intervention Type: Drug
Study Phase: Phase 2
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, With an Active-Treatment Dose-Blinded Period, to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Subjects With Parkinson's Disease
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study, With an Active-Treatment Dose-Blinded Period, to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BIIB054 in Subjects With Parkinson's Disease
Enrollment Status: Terminated
Publish Date: February 28, 2022
Intervention Type: Drug
Study Drug: BIIB054
Study Phase: Phase 2
Effect of LY3154207 on Cognition in Mild-to-Moderate Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)
Effect of LY3154207 on Cognition in Mild-to-Moderate Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or Dementia With Lewy Bodies (DLB)
Enrollment Status: Completed
Publish Date: July 23, 2021
Intervention Type: Drug
Study Phase: Phase 2
Randomized, Multi-center, Open-label, Crossover Pharmacokinetic Study of CVT-301 (Levodopa Inhalation Powder) and an Oral Dose of Carbidopa/Levodopa CD/LD Under Fed Conditions in Patients With Parkinson's Disease
Randomized, Multi-center, Open-label, Crossover Pharmacokinetic Study of CVT-301 (Levodopa Inhalation Powder) and an Oral Dose of Carbidopa/Levodopa CD/LD Under Fed Conditions in Patients With Parkinson's Disease
Enrollment Status: Completed
Publish Date: August 02, 2019
Intervention Type: Drug
Study Phase: Phase 1
View 15 Less Clinical Trials

32 Total Publications

Reply to Trosch et al. Comment on "Dashtipour et al. Dysphagia and Muscle Weakness Secondary to Botulinum Toxin Type A Treatment of Cervical Dystonia: A Drug Class Analysis of Prescribing Information. Toxins 2024, 16, 442".
Reply to Trosch et al. Comment on "Dashtipour et al. Dysphagia and Muscle Weakness Secondary to Botulinum Toxin Type A Treatment of Cervical Dystonia: A Drug Class Analysis of Prescribing Information. Toxins 2024, 16, 442".
Journal: Toxins
Published: March 20, 2025
View All 32 Publications
Similar Doctors
Distinguished in Chorea
Dr. Praveen Dayalu
Neurology
Distinguished in Chorea
Dr. Praveen Dayalu
Neurology

Regents Of The University Of Michigan

4270 Plymouth Rd, 
Ann Arbor, MI 
 (21.1 miles away)
888-287-1082
Languages Spoken:
English, Kannada
See accepted insurances
Accepting New Patients
Offers Telehealth

Praveen Dayalu is a Neurologist in Ann Arbor, Michigan. Dr. Dayalu is rated as a Distinguished provider by MediFind in the treatment of Chorea. His top areas of expertise are Huntington Disease, Movement Disorders, Drug Induced Dyskinesia, and Parkinson's Disease. Dr. Dayalu is currently accepting new patients.

Advanced in Chorea
Dr. Roger L. Albin
Neurology
Advanced in Chorea
Dr. Roger L. Albin
Neurology

Regents Of The University Of Michigan

1500 E Medical Ctr Dr, 
Ann Arbor, MI 
 (24.4 miles away)
Experience:
44+ years
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Roger Albin is a Neurologist in Ann Arbor, Michigan. Dr. Albin has been practicing medicine for over 44 years and is rated as an Elite provider by MediFind in the treatment of Chorea. His top areas of expertise are Parkinson's Disease, Movement Disorders, Huntington Disease, Dementia, and Deep Brain Stimulation. Dr. Albin is currently accepting new patients.

Advanced in Chorea
Dr. Christopher C. Spears
Neurology
Advanced in Chorea
Dr. Christopher C. Spears
Neurology

Regents Of The University Of Michigan

8001 Challis Rd, 
Brighton, MI 
 (22.3 miles away)
810-227-9510
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Christopher Spears is a Neurologist in Brighton, Michigan. Dr. Spears is rated as a Distinguished provider by MediFind in the treatment of Chorea. His top areas of expertise are Progressive Supranuclear Palsy Atypical, Progressive Supranuclear Palsy, Supranuclear Ocular Palsy, and Supranuclear Ophthalmoplegia. Dr. Spears is currently accepting new patients.

VIEW MORE CHOREA DOCTORS

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ellenbogen's expertise for a condition
ConditionClose
  • Elite
  • Drug Induced Dyskinesia
    Dr. Ellenbogen is
    Elite
    . Learn about Drug Induced Dyskinesia.
    See more Drug Induced Dyskinesia experts
  • Movement Disorders
    Dr. Ellenbogen is
    Elite
    . Learn about Movement Disorders.
    See more Movement Disorders experts
  • Parkinson's Disease
    Dr. Ellenbogen is
    Elite
    . Learn about Parkinson's Disease.
    See more Parkinson's Disease experts
  • Distinguished
  • Benign Essential Blepharospasm
    Dr. Ellenbogen is
    Distinguished
    . Learn about Benign Essential Blepharospasm.
    See more Benign Essential Blepharospasm experts
  • Charles Bonnet Syndrome
    Dr. Ellenbogen is
    Distinguished
    . Learn about Charles Bonnet Syndrome.
    See more Charles Bonnet Syndrome experts
  • Dry Mouth
    Dr. Ellenbogen is
    Distinguished
    . Learn about Dry Mouth.
    See more Dry Mouth experts
  • Essential Tremor
    Dr. Ellenbogen is
    Distinguished
    . Learn about Essential Tremor.
    See more Essential Tremor experts
  • Focal Dystonia
    Dr. Ellenbogen is
    Distinguished
    . Learn about Focal Dystonia.
    See more Focal Dystonia experts
  • Restless Legs Syndrome
    Dr. Ellenbogen is
    Distinguished
    . Learn about Restless Legs Syndrome.
    See more Restless Legs Syndrome experts
View All 8 Distinguished Conditions
  • Advanced
  • Alzheimer's Disease
    Dr. Ellenbogen is
    Advanced
    . Learn about Alzheimer's Disease.
    See more Alzheimer's Disease experts
  • Apraxia
    Dr. Ellenbogen is
    Advanced
    . Learn about Apraxia.
    See more Apraxia experts
  • Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency
    Dr. Ellenbogen is
    Advanced
    . Learn about Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency.
    See more Aromatic L-Amino Acid Decarboxylase (AADC) Deficiency experts
  • Athetosis
    Dr. Ellenbogen is
    Advanced
    . Learn about Athetosis.
    See more Athetosis experts
  • Autosomal Dominant Partial Epilepsy with Auditory Features
    Dr. Ellenbogen is
    Advanced
    . Learn about Autosomal Dominant Partial Epilepsy with Auditory Features.
    See more Autosomal Dominant Partial Epilepsy with Auditory Features experts
  • Cerebellar Degeneration
    Dr. Ellenbogen is
    Advanced
    . Learn about Cerebellar Degeneration.
    See more Cerebellar Degeneration experts
View All 50 Advanced Conditions
  • Experienced
  • Accessory Deep Peroneal Nerve
    Dr. Ellenbogen is
    Experienced
    . Learn about Accessory Deep Peroneal Nerve.
    See more Accessory Deep Peroneal Nerve experts
  • Alien Hand Syndrome
    Dr. Ellenbogen is
    Experienced
    . Learn about Alien Hand Syndrome.
    See more Alien Hand Syndrome experts
  • Alternating Hemiplegia of Childhood
    Dr. Ellenbogen is
    Experienced
    . Learn about Alternating Hemiplegia of Childhood.
    See more Alternating Hemiplegia of Childhood experts
  • Anosmia
    Dr. Ellenbogen is
    Experienced
    . Learn about Anosmia.
    See more Anosmia experts
  • Apoplexy
    Dr. Ellenbogen is
    Experienced
    . Learn about Apoplexy.
    See more Apoplexy experts
  • Arachnoid Cysts
    Dr. Ellenbogen is
    Experienced
    . Learn about Arachnoid Cysts.
    See more Arachnoid Cysts experts
View All 93 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile
For Patients
  • Our Story
  • How MediFind Works
  • Conditions A-Z
  • Doctor Directory
  • Symptoms Directory
  • Procedures Directory
  • Treatment Directory
  • Drug Directory
  • Infusion Center Finder
  • FAQ
  • Contact Us
For Providers and Practices
  • Claim Your Profile
  • Newsroom
Business Solutions
  • Provider
  • Network Solutions
Additional Resources
  • Consumer Health Data Privacy Policy
  • Privacy Policy
  • Terms of Use
  • Advertising Policy
  • Content Policy
Subscribe to our newsletter

Sign up to stay informed about MediFind and get wellness sent your way.

Close

    By subscribing, I agree to MediFind's Terms of Use, Privacy Policy and Consumer Health Data Privacy Policy, as applicable.

    Bullet PinMediFind
    Follow us on
    This information is not intended as a substitute for informed medical advice. You should work with a licensed professional to diagnose and treat health conditions. We let the data speak for itself, MediFind does not endorse any healthcare providers.
    © 2026 All Rights Reserved

    Request an Appointment